ArticleBiometrics2025
Semiparametric joint modeling to estimate the treatment effect on a longitudinal surrogate with application to chronic kidney disease trials.
Article in Biometrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In clinical trials where long follow-up is required to measure the primary outcome of interest, there is substantial interest in using an accepted surrogate outcome that can be measured earlier in time or with less cost to estimate a treatment effect. For example, in clinical trials of chronic kidney disease, the effect of a treatment is often demonstrated on a longitudinal surrogate, the change of the longitudinal outcome (glomerular filtration rate, GFR) per year or GFR slope. However, estimating the effect of a treatment on the GFR slope is complicated by the fact that GFR measurement can be terminated by the occurrence of a terminal event, such as death or kidney failure. Thus, to estimate this effect, one must consider both the longitudinal GFR trajectory and the terminal event process. In this paper, we build a semiparametric framework to jointly model the longitudinal outcome and the terminal event, where the model for the longitudinal outcome is semiparametric, the relationship between the longitudinal outcome and the terminal event is nonparametric, and the terminal event is modeled via a semiparametric Cox model. The proposed semiparametric joint model is flexible and can be easily extended to include a nonlinear trajectory of the longitudinal outcome. An estimating equation based method is proposed to estimate the treatment effect on the longitudinal surrogate outcome (eg, GFR slope). Theoretical properties of the proposed estimators are derived, and finite sample performance is evaluated through simulation studies. We illustrate the proposed method using data from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial to examine the effect of Losartan on GFR slope.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.